|
Session 83
Poster Abstracts
Therapeutic Vaccination
Tuesday, 1:30 - 3:30 pm
Poster Hall |
482
 |
Follow-up of a Phase I Trial of the Infusion of Autologous ex vivo CD3/CD28 Co-stimulated and Expanded CD4+T Cells in HIV-1 Infection
Wendy Bernstein*1,2, B Levine3, N Aronson1,4, C Liebig2, H Flaks5, and C June3
1Uniformed Svcs Univ of the Hlth Sci, Bethesda, MD, US; 2Walter Reed Army Inst of Res, Washington, DC, US; 3Univ of Pennsylvania, Phil, PA, US; 4Walter Reed Army Med Ctr, Washington, DC, US; and 5Henry M Jackson Fndn, Rockville, MD, US |
| 483 |
Memory T Cell Responses Induced by Topical DermaVir Vaccine Are Enhanced by IL-7 and IL-15
S Calarota1, A Dai1, J Trocio2, F Lori2, D Weiner1, and Julianna Lisziewicz*3
1Univ of Pennsylvania, Philadelphia, US; 2Res Inst for Genetic and Human Therapy, Washington, DC, US; and 3Genetic Immunity, Washington, DC, US |
484
|
Autologous NEF RNA HIV-1 Electroporated DC Enhances the Detection of CD8-specific Proliferative Responses
Oleg Yegorov*1, B Yassine-Diab1, T Baumgartner1, R Boulassel2, J P Routy2, D Healay3, I Tcherepanova3, C Nicolette3, and R P Sekaly1
1Univ of Montréal, Canada; 2McGill Univ Hlth Ctr, Montreal, Canada; and 3Argos Therapeutics, Durham, NC, US |
| 485 |
DNA Immunotherapy and IL-12 Suppresses Viral Replication following the Cessation of Antiretroviral Drugs
J Boyer1, S Kumar1, R Halwani2, R Parkinson1, L Wu1, G Pavlakis3, B Felber3, M Lewis4, R P Sekaly2, and David Weiner*1
1Univ of Pennsylvania, Philadelphia, US; 2Ctr de Res du CHUM, CANVAC, Montreal, Canada; 3NCI, NIH, DHHS, Bethesda, MD, US; and 4Bioqual, Frederick, MD, US |
486
|
Dendritic Cell-HIV Peptide Therapeutic Vaccination Is Safe and Immunogenic in HIV-infected Subjects with Virologic Suppression
Nancy Connolly*1, S Riddler1, C Wilson2, T Whiteside1, and C Rinaldo1
1Univ of Pittsburgh, PA, US and 2Univ of Colorado Hlth Sci Ctr, Denver, US |
| 487 |
QUEST Study: Follow-up at 1 Year Post-stopping Treatment in Primary HIV Infection Subjects on Long-term ART Randomized to Therapeutic Immunization vs Placebo
Sabine Kinloch*1, F Lampe1, L Perrin2, D Cooper3, B Hoen4, L E Goh5, C Tsoukas6, R El-Habib7, G Theofan8, A Phillips1, and the QUEST Study Group
1Royal Free and Univ Coll Med Sch, London, UK; 2Geneva Univ Hosp, Switzerland; 3Natl Ctr in HIV Epidemiology and Clin Res, Univ of New South Wales, Sydney, Australia; 4CMU Besancon, France; 5GlaxoSmithKline, Greenford, UK; 6McGill Univ, Montreal, Canada; 7Sanofi Pasteur, Lyon, France; and 8Immune Response, Carlsbad, CA, US |
488
|
Cytolitic and Non-cytolitic Antiviral Mechanisms Elicited by HIV-1 Whole Inactivated Vaccine in HAART-naïve, Asymptomatic HIV-infected Individuals
D Trabattoni1, A Gori2, R Maserati3, G Rizzardini4, C Fenizia1, A Marino1, F Mazzotta5, G Theofan6, D Bray7, and Mario Clerici*1
1Univ of Milan, Italy; 2Hosp L Sacco, Milano, Italy; 3IRCCS Policlin San Matteo, Pavia, Italy; 4Hosp di Circolo, Busto Arsizio, Italy; 5Hosp SM Annunziata, Florence, Italy; 6Immune Response, Carlsbad, CA, US; and 7Med Res Council, London, UK |
489
|
Therapeutic Vaccination with Remune Induces CD8+ HIV-1-specific Cytotoxic Responses in Patients with Chronic HIV-1 Infection
Larissa Valor*1, J Navarro1, B Santamaria1, C Rodriguez-Sainz1, J Carbone1, J Gil1, S Moreno2, D Podzamczer3, J Gonzalez-Lahoz4, and E Fernandez-Cruz1
1Univ Gen Hosp Gregorio Marañon, Madrid, Spain; 2Hosp Ramón y Cajal, Madrid, Spain; 3Ciudad Sanitaria Bellvitge, Barcelona, Spain; and 4Inst de Salud Carlos III, Madrid, Spain |
|
